Propanc Biopharma approves 1-for-2 to 1-for-10 reverse stock split
PPCB•Propanc Biopharma authorized a reverse stock split with a ratio between 1-for-2 and 1-for-10. Depending on the ratio, outstanding common shares would fall from approximately 10,331,116 to between 1,033,112 and 5,165,558.
1. Reverse split approved
Propanc Biopharma's board and majority stockholder authorized the reverse stock split on October 6, 2026, through board approval and shareholder written consent. The board will select a ratio between 1-for-2 and 1-for-10 to support financing and capital-raising capacity; the split will take effect when Nasdaq processes and approves the action.
